

ANALOGIC CORP  
Form 10-Q/A  
October 29, 2003  
Table of Contents

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

---

**Amendment No. 1 on**  
**FORM 10-Q/A**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the period ended April 30, 2001

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from            to

Commission file number 0-6715

---

**ANALOGIC CORPORATION**

Edgar Filing: ANALOGIC CORP - Form 10-Q/A

(Exact name of registrant as specified in its charter)

**Massachusetts**  
(State or other jurisdiction of

**04-2454372**  
(I.R.S. Employer

incorporation or organization)

Identification No.)

**8 Centennial Drive**  
**Peabody, Massachusetts**  
(Address of principal executive offices)

**01960**  
(Zip Code)

**(978) 977-3000**

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report.)

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

The number of shares of Common Stock outstanding at May 31, 2001 was 13,017,225.

---

**Table of Contents**

**ANALOGIC CORPORATION**  
**QUARTERLY REPORT ON FORM 10-Q/A**  
**FOR THE QUARTER ENDED APRIL 30, 2001**  
**INTRODUCTORY NOTE**

Pursuant to Rule 12b-15 of the Rules and Regulations under the Securities Exchange Act of 1934, this Amendment on Form 10-Q/A to the Quarterly Report on Form 10-Q of Analogic Corporation (the Company) for the quarter ended April 30, 2001 is being filed to (i) restate the Company's Condensed Consolidated Financial Statements (unaudited) for the three and nine months ended April 30, 2001 and (ii) revise related disclosures included in the Form 10-Q.

On October 15, 2003, the Company reported that it would restate its financial statements for the fiscal years ended July 31, 2002 and July 31, 2001, and condensed financial statements for the quarters within the fiscal years ended July 31, 2003, 2002 and 2001, and would file amended annual reports on Form 10-K/A and amended quarterly reports on Form 10-Q/A. The purpose of this restatement is to reflect the application of the appropriate accounting principles to the recognition of software revenue by Camtronics Medical Systems, Ltd., a 81% owned U.S. subsidiary of the Company, for fiscal years ended July 31, 2003, 2002 and 2001. As restated, the Company's financial results for the three months ended April 30, 2001 reflect a reduction in revenues of \$2,843,000, net income of \$587,000, and diluted earnings per share of \$0.04 and for the nine months ending April 30, 2001 reflect a reduction in revenue of \$4,966,000, net income of \$975,000 and diluted earnings per share of \$0.07. See Note 2, Restatement, of the Notes to Condensed Consolidated Financial Statements for a more complete discussion of the restatement.

This Amendment amends Part I, Items 1 and 2, and Part II, Item 6 of the Quarterly Report on Form 10-Q for the period ended April 30, 2001. This filing should be read in conjunction with the Company's Annual Report on Form 10-K/A for the year ended July 31, 2000, as filed on June 4, 2001 with the Securities and Exchange Commission and the Company's Form 10-Q for the nine months ended April 30, 2000 as filed with the Securities and Exchange Commission on June 9, 2000. This Amendment continues to reflect circumstances as of the date of the original filing of the Quarterly Report on Form 10-Q, and the Company has not updated the disclosures contained therein to reflect events that occurred at a later date, except for items relating to the restatement.

**Table of Contents**

**ANALOGIC CORPORATION**

**INDEX**

	<b><u>Page No</u></b>
<b>Part I. Financial Information</b>	
Item 1. Financial Statements	
<u>Unaudited Condensed Consolidated Balance Sheets as of April 30, 2001 (Restated) and July 31, 2000</u>	4
<u>Unaudited Condensed Consolidated Statements of Income for the Three and Nine Months Ended April 30, 2001 (Restated) and 2000</u>	5
<u>Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended April 30, 2001 (Restated) and 2000</u>	6
<u>Notes to Unaudited Condensed Consolidated Financial Statements</u>	7-18
Item 2. <u>Management's Discussion and Analysis of Results of Operations and Financial Condition</u>	19-27
<b>Part II. Other Information</b>	
Item 6. <u>Exhibits and Reports on Form 8-K</u>	28
<u>Signatures</u>	29
<u>Exhibit Index</u>	30
Certifications	

**Table of Contents****Part I. Financial Information****Item 1. Financial Statements****ANALOGIC CORPORATION****CONDENSED CONSOLIDATED BALANCE SHEETS****(unaudited)****(in thousands)**

	<b>April 30,</b>	<b>July 31,</b>
	<b>2001</b>	<b>2000</b>
	<u>Restated</u>	<u></u>
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 31,119	\$ 29,132
Marketable securities, at market	78,441	87,242
Accounts and notes receivable, net of allowance for doubtful accounts of \$988 at April 30, 2001 and \$1,010 at July 31, 2000	68,772	63,437
Inventory	72,752	62,326
Costs related to deferred revenue	215	
Deferred income taxes	8,721	8,511
Other current assets	6,933	5,239
	<u>266,953</u>	<u>255,887</u>
Total current assets		
Property, plant and equipment, net	66,555	63,524
Investments in and advances to affiliated companies	4,088	4,855
Capitalized software, net	5,981	5,368
Costs related to deferred revenue	2,734	
Other assets	4,025	3,567
	<u>74,383</u>	<u>77,278</u>
Total assets	<u>\$ 350,336</u>	<u>\$ 333,201</u>
<b>LIABILITIES AND STOCKHOLDERS EQUITY</b>		
Current liabilities:		
Mortgage and other notes payable	\$ 367	\$ 363
Obligations under capital leases	328	714
Accounts payable, trade	22,295	20,015
Accrued liabilities	15,543	20,038
Deferred revenue	1,828	
Advance payments and other	2,760	
Accrued income taxes	499	1,780
	<u>43,620</u>	<u>42,910</u>
Total current liabilities		

Edgar Filing: ANALOGIC CORP - Form 10-Q/A

Long-term liabilities:		
Mortgage and other notes payable	4,951	5,265
Obligations under capital leases	658	374
Deferred revenue	4,431	
Deferred income taxes	2,620	2,519
Excess of acquired net assets over cost, net		104
Minority interest in subsidiary	4,023	4,268
	<u>16,683</u>	<u>12,530</u>
Commitments		
Stockholders' equity:		
Common stock, \$.05 par value	703	699
Capital in excess of par value	31,931	27,703
Retained earnings	276,143	266,127
Accumulated other comprehensive income	(1,843)	(2,118)
Treasury stock, at cost	(11,361)	(11,869)
Unearned compensation	(5,540)	(2,781)
	<u>290,033</u>	<u>277,761</u>
Total stockholders' equity	290,033	277,761
	<u>\$ 350,336</u>	<u>\$ 333,201</u>
Total liabilities and stockholders' equity	\$ 350,336	\$ 333,201

The accompanying notes are an integral part of these financial statements.

**Table of Contents****ANALOGIC CORPORATION****CONDENSED CONSOLIDATED STATEMENTS OF INCOME****(unaudited)****(in thousands, except per share data)**

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>April 30,</b>		<b>April 30,</b>	
	<b>2001</b>	<b>2000</b>	<b>2001</b>	<b>2000</b>
	<b>Restated</b>		<b>Restated</b>	
Net revenue:				
Product	\$ 78,606	\$ 66,837	\$ 230,923	\$ 178,690
Engineering	6,852	5,323	18,920	15,774
Other	2,785	2,910	9,542	9,334
<b>Total net revenue</b>	<b>88,243</b>	<b>75,070</b>	<b>259,385</b>	<b>203,798</b>
Costs of sales:				
Product	50,792	41,710	149,462	112,832
Engineering	5,367	4,346	15,398	13,082
Other	1,669	1,508	4,901	4,496
<b>Total cost of sales</b>	<b>57,828</b>	<b>47,564</b>	<b>169,761</b>	<b>130,410</b>
<b>Gross margin</b>	<b>30,415</b>	<b>27,506</b>	<b>89,624</b>	<b>73,388</b>
Operating expenses:				
Research and product development	10,569	8,382	28,966	26,416
Selling and marketing	8,612	6,728	23,782	19,015
General and administrative	7,909	6,396	22,902	17,729
	27,090	21,506	75,650	63,160
<b>Income from operations</b>	<b>3,325</b>	<b>6,000</b>	<b>13,974</b>	<b>10,228</b>
Other (income) expense:				
Interest income, net	(1,314)	(1,404)	(4,254)	(4,419)
Equity in unconsolidated affiliates	(1,331)	137	(1,192)	1,946
Other, net	94	10	516	(37)
	(2,551)	(1,257)	(4,930)	(2,510)
<b>Income before income taxes and minority interest</b>	<b>5,876</b>	<b>7,257</b>	<b>18,904</b>	<b>12,738</b>
Provision for income taxes	1,565	2,250	5,803	3,950
Minority interest	42	10	89	85

Edgar Filing: ANALOGIC CORP - Form 10-Q/A

Net Income	\$ 4,269	\$ 4,997	\$ 13,012	\$ 8,703
Earnings per common share:				
Basic	\$ 0.33	\$ 0.39	\$ 1.01	\$ 0.68
Diluted	0.33	0.39	1.00	0.68

The accompanying notes are an integral part of these financial statements.



**Table of Contents****ANALOGIC CORPORATION****CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS****(unaudited)****(in thousands)**

	<b>Nine Months Ended April 30,</b>	
	<b>2001</b>	<b>2000</b>
	<b>Restated</b>	
<b>OPERATING ACTIVITIES:</b>		
Net Income	\$ 13,012	\$ 8,703
Adjustments to reconcile net income to net cash provided (used) by operating activities:		
Deferred income taxes	(109)	(1,190)
Depreciation and amortization	10,128	9,793
Minority interest in net income of consolidated subsidiaries	90	85
Allowance for doubtful accounts	(22)	587
Gain on sale of equipment	(51)	(61)
Excess of equity in (gain) loss of unconsolidated affiliates	(1,192)	1,946
Loss on investment	487	
Compensation from stock grants	734	444
Net changes in operating assets and liabilities	(15,696)	(21,281)
<b>NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES</b>	<b>7,381</b>	<b>(974)</b>
<b>INVESTING ACTIVITIES:</b>		
Investments in and advances to affiliated companies		(2,744)
Return of investment from affiliated company	1,000	
Additions to property, plant and equipment	(11,940)	(9,481)
Capitalized software	(2,369)	(2,474)
Proceeds from sale of property, plant and equipment	109	92
Purchases of marketable securities		(7,805)
Maturities of marketable securities	10,320	11,905
<b>NET CASH USED IN INVESTING ACTIVITIES</b>	<b>(2,880)</b>	<b>(10,507)</b>
<b>FINANCING ACTIVITIES:</b>		
Payments on debt and capital lease obligations	(412)	(770)
Issuance of common stock pursuant to exercise of stock options and employee stock purchase plan	1,230	941
Dividends paid to shareholders	(2,714)	(2,689)
<b>NET CASH USED IN FINANCING ACTIVITIES</b>	<b>(1,896)</b>	<b>(2,518)</b>
<b>EFFECT OF EXCHANGE RATE CHANGES ON CASH</b>	<b>(618)</b>	<b>(25)</b>
<b>NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b>	<b>1,987</b>	<b>(14,024)</b>

Edgar Filing: ANALOGIC CORP - Form 10-Q/A

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	29,132	30,017
CASH AND CASH EQUIVALENTS, END OF PERIOD	\$ 31,119	\$ 15,993

The accompanying notes are an integral part of these financial statements.

**Table of Contents**

**ANALOGIC CORPORATION**

**NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(in thousands, except per share data)**

**1. Basis of Presentation:**

The unaudited condensed consolidated financial statements of Analogic Corporation (the Company) presented herein have been prepared pursuant to the rules of the Securities and Exchange Commission (SEC) for quarterly reports on Form 10-Q and do not include all of the information and note disclosures required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary for a fair presentation of the results for all periods presented. The results of the operations for the three and nine months ended April 30, 2001 are not necessarily indicative of the results to be expected for the fiscal year ending July 31, 2001, or any other interim period.

These statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended July 31, 2000, included in the Company's Form 10-K/A as filed with the SEC on June 4, 2001, and the Company's Form 10-Q for the nine months ended April 30, 2000 as filed with the SEC on June 9, 2000.

The condensed financial statements have not been audited by independent certified public accountants. The condensed consolidated balance sheet as of July 31, 2000, contains data derived from audited financial statements.

Certain financial statement items have been reclassified to conform to the current year's financial presentation format.

**2. Restatement:**

The Company has restated its prior period condensed financial statements to reflect the application of the appropriate accounting principles to the recognition of software revenue by its subsidiary Camtronics Medical Systems, Ltd. As restated, the Company's financial results for the three months ended April 30, 2001 reflect a reduction in revenues of \$2,843, net income of \$587, and diluted earnings per share of \$0.04 and for the nine months ended April 30, 2001 reflect a reduction in revenue of \$4,966, net income of \$975 and diluted earnings per share of \$0.07, compared to the Company's financial results previously reported for the three and nine months ended April 30, 2001.

Summarized below is a more detailed discussion of the restatement along with a comparison of the amounts previously reported in the condensed balance sheet and statements of operations in Form 10-Q/A as of and for the three and nine months ended April 30, 2001.

## Edgar Filing: ANALOGIC CORP - Form 10-Q/A

In connection with the preparation of its Financial Statements for the fiscal year ended July 31, 2003 the Company concluded that its accounting for revenue at its Camtronics subsidiary did not meet required accounting standards. The Company has taken steps to ensure that Camtronics sales transactions will be properly accounted for in the future.

Camtronics previously accounted for all of its revenues in accordance with Staff Accounting Bulletin 101, Revenue Recognition ( SAB 101 ). The Company has determined that Camtronics revenue recognition policy should be in accordance with American Institute of Certified Public Accountants (AICPA) Statement of Position 97-2, Software Revenue Recognition ( SOP 97-2 ). Accordingly, certain revenues originally recorded in prior periods should have been deferred. In accordance with SAB 101, the Company had previously recognized revenue when the major components of software had been delivered, installed, and accepted by the customer. In the majority of sales transactions involved in the restatement, the customer has already installed and paid for the software it had accepted. As required by SOP 97-2, the Company will recognize the total revenue related to transactions involving software once all components are delivered, installed, and accepted by the customer.

**Table of Contents**

**ANALOGIC CORPORATION**

**NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Continued)**

Camtronics revenues are derived primarily from the sale of Digital Cardiac Information Systems. System sales revenues consist of the following components: computer software licenses, computer hardware, installation support, and sublicensed software. In addition, Camtronics generates revenues related to system sales for software support, hardware maintenance, training, consulting and other professional services.

Camtronics recognizes revenue in accordance with the provisions of SOP 97-2. SOP 97-2 requires revenue earned on software arrangements involving multiple-elements to be allocated to each element based on the fair values of those elements or by use of the residual method. Under the residual method, revenue is recognized in a multiple-element arrangement when vendor-specific objective evidence ( VSOE ) of fair value exists for all of the undelivered elements in the arrangement, which is determined by the price charged when that element is sold separately (i.e. professional services, software support, hardware maintenance, hardware and sublicensed software), but does not exist for one or more of the delivered elements in the arrangement (i.e. software solutions). Specifically, Camtronics determines the fair value of the maintenance portion of the arrangement based on the renewal price of the maintenance charged to clients, professional services portion of the arrangement, other than installation services, based on hourly rates which Camtronics charges for these services when sold apart from a software license, and the hardware and sublicensed software based on the prices for these elements when they are sold separately from the software. If evidence of the fair value cannot be established for the undelivered elements of a license agreement, the entire amount of revenue under the arrangement is deferred until these elements have been delivered or objective evidence of fair value for the remaining undelivered element is established.

Inherent in the revenue recognition process are significant management estimates and judgments, which influence the timing and the amount of revenue recognition. Camtronics provides several models for the procurement of its digital cardiac information systems. The predominant model includes a perpetual software license agreement, project-related installation services, professional consulting services, computer hardware and sub-licensed software and software support.

Camtronics provides installation services, which include project-scoping services, conducting pre-installation audits detailed installation plans, actual installation of hardware components, and testing of all hardware and software installed at the customer site. Because installation services are deemed to be essential to the functionality of the software, software license and installation services fees are recognized upon completion of installation.

Camtronics also provides professional consulting services, which include consulting activities that fall outside of the scope of the standard installation services. These services vary depending on the scope and complexity requested by the client. Examples of such services may include additional database consulting, system configuration, project management, interfacing to existing systems, and network consulting. Professional consulting services generally are not deemed to be essential to the functionality of the software, and thus, do not impact the timing of the software license revenue recognition. Professional consulting service revenue is recognized as the services are performed.

Hardware and software maintenance fees are marketed under annual and multi-year arrangements and are recognized as revenue ratably over the contracted maintenance term.

## Edgar Filing: ANALOGIC CORP - Form 10-Q/A

Deferred revenue is comprised of 1) license fee, maintenance and other service revenues for which payment has been received and for which services have not yet been performed and 2) revenues which had been invoiced, and paid in the majority of cases, related to delivered components of a multiple-element arrangement for which fair value has not been determined for components not yet delivered or accepted by the customer. Costs related to deferred revenue represents costs of goods sold and services provided and sales commission expenses.

Deferred Revenue and costs related to deferred revenue which have been classified within the Balance Sheet as long-term represent specific transactions where Camtronics has determined that it will not meet VSOE requirements for these transactions under SOP 97-2 within the next twelve calendar months.

**Table of Contents****ANALOGIC CORPORATION****NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****(Continued)**

The following tables show the effect of the restatement on the Company's Statement of Operations and Balance Sheet.

***Statements of Operations:***

	<b>Three Months Ended</b>		
	<b>April 30, 2001</b>		
	<b>Previously</b>	<b>(unaudited)</b>	
	<b>Reported</b>	<b>Restated</b>	<b>Changes</b>
Net revenue:			
Product	\$ 81,449	\$ 78,606	\$ (2,843)(a)
Engineering	6,852	6,852	
Other	2,785	2,785	
	<u>91,086</u>	<u>88,243</u>	<u>(2,843)</u>
Total net revenue			
Costs of sales:			
Product	52,200	50,792	(1,408)(b)
Engineering	5,367	5,367	
Other	1,669	1,669	
	<u>59,236</u>	<u>57,828</u>	<u>(1,408)</u>
Total cost of sales			
Gross margin	31,850	30,415	(1,435)
Operating expenses:			
Research and product development	10,641	10,569	(72)(c)
Selling and marketing	8,813	8,612	(201)(d)
General and administrative	7,909	7,909	
	<u>27,363</u>	<u>27,090</u>	<u>(273)</u>
Income from operations:	4,487	3,325	(1,162)
Other (income) expense:			
Interest income, net	(1,314)	(1,314)	
Equity in unconsolidated affiliates	(1,331)	(1,331)	

Edgar Filing: ANALOGIC CORP - Form 10-Q/A

Other, net	94	94	
	<u>(2,551)</u>	<u>(2,551)</u>	
Income before income taxes and minority interest	7,038	5,876	(1,162)
Provision for income taxes	2,006	1,565	(441)(e)
Minority interest	176	42	(134)(f)
	<u>          </u>	<u>          </u>	<u>          </u>
Net income	\$ 4,856	\$ 4,269	\$ (587)
	<u>          </u>	<u>          </u>	<u>          </u>
Earnings per common share:			
Basic	\$ 0.37	\$ 0.33	\$ (0.04)
Diluted	0.37	0.33	(0.04)(g)



**Table of Contents****ANALOGIC CORPORATION****NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****(Continued)**

Statements of Operations components increased (decreased) as a result of the following:

(a)	<i>Net Revenue: Product</i>	
	Adjust recognition of revenue for application of SOP 97-2	\$ (2,843)
		<u>          </u>
(b)	<i>Cost of sales: Products</i>	
	Adjust cost of sales related to transactions for which revenue has been deferred	\$ (1,480)
	Reclassifications not impacting net income	72
		<u>          </u>
	Net decrease	\$ (1,408)
		<u>          </u>
(c)	<i>Research and product development</i>	
	Reclassifications not impacting net income	\$ (72)
		<u>          </u>
(d)	<i>Selling and marketing</i>	
	Adjust the commission expense related to transactions for which revenue has been deferred	\$ (201)
		<u>          </u>
(e)	<i>Provision for income taxes</i>	
	Net decrease to provision due to above adjustments	\$ (441)
		<u>          </u>
(f)	<i>Minority interest</i>	
	Decrease in minority interest due to above adjustments	\$ (134)
		<u>          </u>
(g)	<i>Net earnings per common share: Diluted</i>	
	Net effect to diluted earnings per share due to above adjustments	\$ (0.04)
		<u>          </u>

**Table of Contents****ANALOGIC CORPORATION****NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****(Continued)***Statements of Operations:*

	Nine Months Ended		
	April 30, 2001		
	Previously Reported	(unaudited) Restated	Changes
Net revenue:			
Product	\$ 235,889	\$ 230,923	\$ (4,966)(a)
Engineering	18,920	18,920	
Other	9,542	9,542	
Total net revenue	264,351	259,385	(4,966)
Costs of sales:			
Product	151,192	149,462	(1,730)(b)
Engineering	15,398	15,398	
Other	4,901	4,901	
Total cost of sales	171,491	169,761	(1,730)
Gross margin	92,860	89,624	(3,236)
Operating expenses:			
Research and product development	30,134	28,966	(1,168)(c)
Selling and marketing	24,115	23,782	(333)(d)
General and administrative	22,902	22,902	
	77,151	75,650	(1,501)
Income from operations:	15,709	13,974	(1,735)
Other (income) expense:			
Interest income, net	(4,254)	(4,254)	
Equity in unconsolidated affiliates	(1,192)	(1,192)	
Other, net	516	516	
	(4,930)	(4,930)	

Edgar Filing: ANALOGIC CORP - Form 10-Q/A

Income before income taxes and minority interest	20,639	18,904	(1,735)
Provision for income taxes	6,358	5,803	(555)(e)
Minority interest	294	89	(205)(f)
Net Income	\$ 13,987	\$ 13,012	\$ (975)
Earnings per common share:			
Basic	\$ 1.08	\$ 1.01	\$ (0.07)
Diluted	1.07	1.00	(0.07)(g)

**Table of Contents****ANALOGIC CORPORATION****NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****(Continued)**

Statements of Operations components increased (decreased) as a result of the following:

(a)	<i>Net Revenue: Product</i>	
	Adjust recognition of revenue for application of SOP 97-2	\$ (4,966)
		<u>          </u>
(b)	<i>Cost of sales: Product</i>	
	Adjust cost of sales related to transactions for which revenue has been deferred	\$ (2,898)
	Reclassification not impacting net income	1,168
		<u>          </u>
	Net decrease	\$ (1,730)
		<u>          </u>
(c)	<i>Research and product development</i>	
	Reclassification not impacting net income	\$ (1,168)
		<u>          </u>
(d)	<i>Selling and marketing</i>	
	Adjust the commission expense related to transactions for which revenue has been deferred	\$ (333)
		<u>          </u>
(e)	<i>Provision for income taxes</i>	
	Net decrease to provision due to above adjustments	\$ (555)
		<u>          </u>
(f)	<i>Minority interest</i>	
	Decrease in minority interest earnings due to above adjustments	\$ (205)
		<u>          </u>
(g)	<i>Net earnings per common share: Diluted</i>	
	Net effect to diluted earnings per share due to above adjustments	\$ (0.07)
		<u>          </u>

**Table of Contents****ANALOGIC CORPORATION****NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****(Continued)****Balance Sheets:**

	April 30, 2001		
	Previously	Unaudited	
	Reported	Restated	Changes
<b>ASSETS</b>			
Current assets:			
Cash and cash equivalents	\$ 31,119	\$ 31,119	
Marketable securities, at market	78,441	78,441	
Accounts and notes receivable, net of allowance for doubtful accounts	68,772	68,772	
Inventory	72,752	72,752	
Costs related to deferred revenue		215	\$ 215(a)
Deferred income taxes	8,067	8,721	654(b)
Other current assets	6,933	6,933	
	<u>266,084</u>	<u>266,953</u>	<u>869</u>
Total current assets			
Property, plant and equipment, net	66,555	66,555	
Investments in and advances to affiliated companies	4,088	4,088	
Capitalized software, net	5,981	5,981	
Costs related to deferred revenue		2,734	2,734(c)
Other assets	4,025	4,025	
	<u>\$ 346,733</u>	<u>\$ 350,336</u>	<u>\$ 3,603</u>
<b>LIABILITIES AND STOCKHOLDERS EQUITY</b>			
Current liabilities:			
Mortgage and other notes payable	\$ 367	\$ 367	
Obligations under capital leases	328	328	
Accounts payable, trade	22,295	22,295	
Accrued liabilities	19,878	15,543	\$ (4,335)(d)
Deferred revenue		1,828	1,828(e)
Advance payments and other		2,760	2,760(f)
Accrued income taxes	401	499	98(g)
	<u>43,269</u>	<u>43,620</u>	<u>351</u>
Total current liabilities			
Long-term liabilities:			
Mortgage and other notes payable	4,951	4,951	
Obligations under capital leases	658	658	

Edgar Filing: ANALOGIC CORP - Form 10-Q/A

Deferred revenue		4,431	4,431(h)
Deferred income taxes	2,620	2,620	
Minority interest in subsidiary	4,227	4,023	(204)(i)
	<u>12,456</u>	<u>16,683</u>	<u>4,227</u>
<b>Commitment</b>			
Stockholders' equity:			
Common stock, \$.05 par value	703	703	
Capital in excess of par value	31,931	31,931	
Retained earnings	277,118	276,143	(975)(j)
Accumulated other comprehensive income	(1,843)	(1,843)	
Treasury stock, at cost	(11,361)	(11,361)	
Unearned compensation	(5,540)	(5,540)	
	<u>291,008</u>	<u>290,033</u>	<u>(975)</u>
Total stockholders' equity			
Total liabilities and stockholders' equity	\$ 346,733	\$ 350,336	\$ 3,603

Table of Contents

## ANALOGIC CORPORATION

## NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Continued)

The increases (decreases) to the balance sheet components are due to current period recognition of current period deferrals of revenue and related costs and the cumulative effect at the beginning of the quarter for the restatements of prior periods for similar matters. On a net basis the balance sheet components increased (decreased) due to the following:

(a)	<i>Costs related to deferred revenue (short-term)</i>	
	Deferred costs related to deferred revenue	\$ 215
		<u>          </u>
(b)	<i>Deferred income taxes</i>	
	Deferred income tax related to deferred costs and revenue	\$ 654
		<u>          </u>
(c)	<i>Costs related to deferred revenue (long-term)</i>	
	Deferred costs related to deferred revenue	\$ 2,734
		<u>          </u>
(d)	<i>Accrued liabilities</i>	
	Reclassification not impacting net income	\$ (4,588)
	Deferred revenue classified as short-term	535
	Accrued warranty costs related to deferred revenue	(282)
		<u>          </u>
	Net decrease	\$ (4,335)
		<u>          </u>
(e)	<i>Deferred revenue (short-term)</i>	
	Deferred revenue classified as short-term	\$ 1,828
		<u>          </u>
(f)	<i>Advance payments and other (short-term)</i>	
	Reclassification not impacting net income	\$ 2,760
		<u>          </u>
(g)	<i>Accrued income taxes</i>	
	Tax provision adjusted for the change to net income	\$ 98
		<u>          </u>
(h)	<i>Deferred revenue (long-term)</i>	
	Deferred revenue classified as long-term	\$ 4,431
		<u>          </u>
(i)	<i>Minority interest</i>	
	Adjust minority interest due to above adjustments	\$ (204)
		<u>          </u>
(j)	<i>Retained earnings</i>	

Edgar Filing: ANALOGIC CORP - Form 10-Q/A

Net effect to retained earnings from above adjustments:

Effect for the nine months ended April 30, 2001

\$ (975)

---



**Table of Contents****ANALOGIC CORPORATION****NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****(Continued)****3. Balance sheet information:**

Additional information for certain balance sheet accounts is as follows for the periods indicated:

	<b>April 30,</b>	<b>July 31,</b>
	<b>2001</b>	<b>2000</b>
	<u>          </u>	<u>          </u>
<b>Inventory:</b>		
Raw materials	\$ 40,768	\$ 31,728
Work-in-process	21,436	20,724
Finished goods	10,548	9,874
	<u>          </u>	<u>          </u>
	<b>\$ 72,752</b>	<b>\$ 62,326</b>
	<u>          </u>	<u>          </u>
<b>Accrued liabilities (Restated):</b>		
Employee compensation and benefits	\$ 9,869	\$ 10,562
Warranty	3,218	3,636
Other	2,456	3,068
	<u>          </u>	<u>          </u>
	<b>\$ 15,543</b>	<b>\$ 17,266</b>
	<u>          </u>	<u>          </u>

**4. Investment in and Advances to Affiliated Companies:****A. Investment in Shenzhen Anke-Tech Co., Ltd:**

During October 2000, Analogic Scientific, Inc. (ASI), a joint venture corporation located in The People's Republic of China, entered into separate agreements with four investors which resulted in these investors buying an 10.8% equity interest in ASI from its existing investors. This transaction had the approval of the Company and the other shareholder who prior to this transaction each had a 50% equity ownership interest in ASI. As a result, the Company's ownership in ASI was reduced by 5.4% to 44.6%. On January 18, 2001, the company name was changed from Analogic Scientific, Inc. to Shenzhen Anke High-Tech Co., Ltd (SAHCO).

## Edgar Filing: ANALOGIC CORP - Form 10-Q/A

The Company accounts for this investment under the equity method of accounting whereby the Company adjusts its investment balance to recognize its share of SAHCO's earnings or losses, changes in SAHCO's capital investment and dividends received.

SAHCO has historically provided the Company with current quarterly information regarding its financial results. To ensure that the Company has adequate time to review and adjust the financial information provided by SAHCO to conform it to U.S. Generally Accepted Accounting Principles (GAAP), the Company changed, effective with the quarter ended October 31, 2000, its method of recording SAHCO's financial results and uses the previous quarter's financial information of SAHCO to adjust its investment account in the current quarter, thereby resulting in a consistently applied quarterly delay in recording its equity-based accounting.

During fiscal 2001 the Company became aware of certain differences between local statutory accounting practices used by SAHCO and U.S. GAAP primarily with respect to the valuation of accounts receivable and inventory and revenue recognition. During the quarter ended January 31, 2001, the Company evaluated the potential differences in accounting basis and concluded that adjustments were necessary for prior periods resulting in a reduction in the Company's investment in SAHCO of \$2,375,000 at July 31, 2000 (or \$1,808,000 net of tax effect) which reduced the carrying value of the Company's investment at July 31, 2000 from \$6,125,000 to \$3,750,000.

**Table of Contents****ANALOGIC CORPORATION****NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****(Continued)**

As a result of the sale of a 5.4% equity interest in SAHCO, the Company recognized a gain of \$810,000 in the quarter ended April 30, 2001. In addition, the Company recognized its share of SAHCO's quarterly profit of \$15,000 in the quarter ended April 30, 2001. The carrying value of the Company's investment in SAHCO at April 30, 2001 was \$3,225,000.

**B. Other Investments:**

During the quarter ended April 30, 2001 the Company received \$1,000,000 as a return on investment from a joint venture which generated income from license related royalties based upon sales of medical imaging equipment.

**5. Dividends:**

The Company declared dividends of \$.07 per common share on June 12, 2001, payable July 10, 2001 to shareholders of record on June 26, 2001. The Company declared dividends of \$.07 per common share on March 15, 2001, payable on April 12, 2001 to shareholders of record on March 29, 2001, \$.07 per common share on December 5, 2000, payable on January 9, 2001 to shareholders of record on December 26, 2000 and \$.07 per common share on October 12, 2000, payable on November 10, 2000 to shareholders of record on October 27, 2000.

**6. Comprehensive Income:**

The following table presents the calculation of total comprehensive income and its components:

	<b>Three Months</b>		<b>Nine Months</b>	
	<b>Ended</b>		<b>Ended</b>	
	<b>April 30,</b>		<b>April 30,</b>	
	<b>2001</b>	<b>2000</b>	<b>2001</b>	<b>2000</b>
	<b>Restated</b>		<b>Restated</b>	
Net income	\$ 4,269	\$ 4,997	\$ 13,012	\$ 8,703

Edgar Filing: ANALOGIC CORP - Form 10-Q/A

Other comprehensive income (loss) net of tax:

Unrealized holding gains and losses, net of taxes of \$80 and \$58 for the three months ended April 30, 2001 and 2000 and \$600 and \$592 for the nine months ended April 30, 2001 and 2000	(121)	(130)	918	(1,319)
Foreign currency translation adjustment, net of taxes of \$328 and \$270 for the three months ended April 30, 2001 and 2000, and \$417 and \$530 for the nine months ended April 30, 2001 and 2000	(502)	(602)	(643)	(1,179)
<b>Total Comprehensive Income</b>	<b>\$ 3,646</b>	<b>\$ 4,265</b>	<b>\$ 13,287</b>	<b>\$ 6,205</b>

**7. Net income per share:**

The following table sets forth the computation of basic and diluted earnings per share:

	Three Months Ended		Nine Months Ended	
	April 30,		April 30,	
	2001	2000	2001	2000
	<b>Restated</b>		<b>Restated</b>	
Net income	\$ 4,269	\$ 4,997	\$ 13,012	\$ 8,703
Basic:				
Weighted average number of common shares outstanding	12,992,491	12,857,841	12,900,504	12,800,207
Net income per share	\$ 0.33	\$ 0.39	\$ 1.01	\$ 0.68
Diluted:				
Weighted average number of common shares outstanding	12,992,491	12,857,841	12,900,504	12,800,207
Dilutive effect of stock options	134,650	82,318	143,604	58,362
Total	13,127,141	12,940,159	13,044,108	12,858,569
Net income per share	\$ 0.33	\$ 0.39	\$ 1.00	\$ 0.68

**Table of Contents****ANALOGIC CORPORATION****NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****(Continued)****8. Commitments:**

The Company's Danish subsidiary B-K Medical A/S announced in May 2001 the construction of a new 135,000 square foot facility in Herlev, north of Copenhagen, for the manufacture of specialized diagnostic ultrasound equipment at an estimated cost of \$15.5 million. The new facility, due for completion in April 2002, will host manufacturing, R&D, service, marketing, sales and administrative functions.

**9. Supplemental disclosure of cash flow information:**

Changes in operating assets and liabilities are as follows:

	<b>Nine Months Ended April 30,</b>	
	<b>2001</b>	<b>2000</b>
	<b>Restated</b>	
Accounts and notes receivable	\$ (6,428)	\$ (755)
Accounts receivable from affiliates	1,111	(28)
Inventory	(10,442)	(17,342)
Costs related to deferred revenue	(2,949)	
Other current assets	(1,694)	(372)
Other assets	(456)	(2,179)
Accounts payable trade	2,290	4,177
Accrued expenses and other current liabilities	4,609	(2,831)
Accrued income taxes	(1,737)	(1,951)
	<hr/>	<hr/>
Net changes in operating assets and liabilities	<b>\$ (15,696)</b>	<b>\$ (21,281)</b>
	<hr/>	<hr/>

**10. Segment information:**

The Company's operations are primarily within a single segment within the electronics industry (Medical Instrumentation Technology Products). These operations encompass the design, manufacture and sale of high technology, high-performance, high precision data acquisition, conversion

## Edgar Filing: ANALOGIC CORP - Form 10-Q/A

(analog/digital) and signal processing instruments and systems to customers that both manufacture and market products for medical and industrial use. The other segment represents the Company's hotel operation, and other Company's operations, which do not meet the materiality requirements of the statement of Financial Accounting Standards (SFAS) No. 131, Disclosures About Segments of an Enterprise and Related Information, and thus are not required to be separately disclosed. The table below presents information about the Company's reportable segments for the periods presented:

	Three Months Ended		Nine Months Ended	
	April 30,		April 30,	
	2001	2000	2001	2000
	Restated		Restated	
<b>Revenues:</b>				
Medical Instrumentation Technology Products	\$ 78,605	\$ 68,675	\$ 231,319	\$ 184,923
Corporate and Other	9,638	6,395	28,066	18,875
<b>Total</b>	<b>\$ 88,243</b>	<b>\$ 75,070</b>	<b>\$ 259,385</b>	<b>\$ 203,798</b>
<b>Income before income taxes and minority interest:</b>				
Medical Instrumentation Technology Products	\$ 4,173	\$ 6,064	\$ 12,757	\$ 8,821
Corporate and Other	1,703	1,193	6,147	3,917
<b>Total</b>	<b>\$ 5,876</b>	<b>\$ 7,257</b>	<b>\$ 18,904</b>	<b>\$ 12,738</b>

**Table of Contents**

	<b>April 30, 2001</b>	<b>July 31, 2000</b>
	<b>Restated</b>	
Identifiable Assets:		
Medical Instrumentation Technology Products	\$ 235,261	\$ 212,634
Corporate and Other, including Cash and Marketable Securities	115,075	120,567
<b>Total</b>	<b>\$ 350,336</b>	<b>\$ 333,201</b>

**Table of Contents**

**ANALOGIC CORPORATION**

**Item 2. Management's Discussion and Analysis of Results of Operations and Financial Condition.**

The following information has been amended to reflect the revisions made to the Condensed Consolidated Financial Statements as further discussed in Note 2, Restatement. This information should be read in conjunction with the information contained in the Unaudited Condensed Consolidated Financial Statements, and Notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q/A. This Quarterly Report on Form 10-Q/A contains forward-looking statements that involve risks and uncertainties. See the discussion relating to Forward-Looking Statements below.

**Results of Operations**

*Nine Months Fiscal 2001 (04/30/01) vs. Nine Months Fiscal 2000 (04/30/00)*

Product revenue for the nine months ended April 30, 2001 was \$230,923,000 as compared to \$178,690,000 for the same period last year, an increase of 29%. The increase in revenue of \$52,233,000 was due to an increase in sales of Medical Technology Products of \$46,290,000 or 36%, primarily due to increased demand for fully featured mid-range Computed Tomography (CT) systems, digital radiography systems, patient monitors, and advanced cardiovascular information management systems; an increase in sales of \$11,246,000 or 67%, in Industrial Technology Products due to demand for the Company's high frequency, Automatic Test Equipment (ATE) boards; partially offset by a decrease in Signal Processing Technology Products of \$5,303,000 or 15%, caused by a dramatic downturn in demand for its network access boards for the Internet Telephony market. Engineering revenue for the nine months ended April 30, 2001 was \$18,920,000 as compared to \$15,774,000 for the same period last year, an increase of 20%. The increase of \$3,146,000 was primarily due to customer funded projects for developing imaging products and Media Gateway Systems. Other revenue represents revenue from the Hotel operation.

Product cost of sales for first the nine months of fiscal 2001 was 65% of product revenue compared to 63% for the same period last year. The increase in product cost as percentage of product revenue was primarily due to higher manufacturing costs and changes in product mix. Engineering cost of sales for the first nine months of fiscal 2001 was 81% of engineering revenue or compared to 83% for the same period last year. Other cost of sales represents costs associated with the Hotel operation.

Research and product development expenses were \$28,966,000 or 11% of total revenue, for the first nine months of fiscal 2001, as compared to \$26,416,000 or 13% of total revenue for the same period of the prior year. The increase of \$2,550,000 was due to the continuing research and development activities across all of the Company's product lines.

Selling and marketing expenses were \$23,782,000 or 9% of total revenue, and \$19,015,000 or 9% of total revenue, for the first nine months of fiscal 2001, and 2000, respectively. The increase of \$4,767,000 was due to higher personnel and related selling costs of approximately \$2,267,000 for the Company's Camtronic subsidiary which is continuing its efforts of selling products directly to end users as compared to its prior practice of selling through OEMs. The remaining increase of \$2,500,000 is primarily associated with additional selling and marketing efforts to support the Company's revenue growth.



## Edgar Filing: ANALOGIC CORP - Form 10-Q/A

General and administrative expenses for the first nine months of fiscal 2001 were \$22,902,000 as compared to \$17,729,000 for the same period last year, or 9% of total revenue in both periods. The increase of \$5,173,000 was primarily due to higher personnel and other related costs to support the Company's growth.

## **Table of Contents**

Computer software costs of \$2,366,000 and \$2,434,000 were capitalized in the first nine months of fiscal 2001 and 2000, respectively. Amortization of capitalized software amounted to \$1,389,000 and \$1,326,000 in the first nine months of fiscal 2001 and 2000, respectively, and is included in product cost of sales.

Interest income, net of interest expense, for the first nine months of fiscal 2001 was \$4,254,000 as compared with \$4,419,000 for the same period last year. Interest income, net represents primarily interest earned on marketable securities.

During the nine months ended April 30, 2001, the Company recorded income of \$1,192,000 related to equity in unconsolidated affiliates. The amount primarily consists of a profit of \$1,245,000 related to its share in a joint venture that generated income from license related royalties based upon sales of medical imaging equipment. This was partially offset by the Company's share of net losses of \$111,000 from the Company's investment in SAHCO. During the nine months ended April 30, 2000, the Company recorded losses of \$1,946,000 related to equity in its unconsolidated affiliates. The Company recorded its share of losses in a joint venture of \$2,267,000 related to research and development costs for the design and manufacture of medical equipment. This joint venture was restructured during fiscal 2000 whereby the joint venture received license related royalties based upon the sales of medical imaging equipment. This loss was partially offset by a gain of \$450,000 reflecting the Company's share of profit of SAHCO.

Other expenses of \$516,000 during the nine months ended April 30, 2001 are mainly related to a writedown of approximately \$487,000 which reflects the difference between the Company's investment cost and the current market value of the restricted securities the Company received during fiscal 2000 as a final distribution of shares in a publicly traded company made by a limited partnership in which the Company had invested.

The effective tax rate for the first nine months of fiscal 2001 and 2000 was 31%.

Net income for the nine months ended April 30, 2001 was \$13,012,000 or \$1.00 per diluted share as compared with \$8,703,000 or \$.68 per diluted share for the same period last year. The increased performance over the prior year was primarily due to increased sales volume of fully featured mid-range Computed Tomography (CT) systems, Automatic Test Equipment (ATE) boards and advanced cardiovascular radiography systems partially offset by the Company's previously discussed share of loss in SAHCO and the writedown of the investment in restricted securities received from a limited partnership to market value.

## **Results of Operations**

### ***Third Quarter Fiscal 2001 (04/30/01) vs. Third Quarter Fiscal 2000 (04/30/00)***

Product revenue for the three months ended April 30, 2001 was \$78,606,000 as compared to \$66,837,000 for the same period last year, an increase of 18%. The increase of \$11,769,000 was primarily due to an increase in sales Medical Technology Products of \$14,916,000 or 32%, due to increased demand for fully featured mid-range Computed Tomography (CT) systems, patient monitors, and advanced cardiovascular information management systems, partially offset by a decrease in sales of \$3,371,000 or 27%, in Signal Processing Technology Products primarily due to lower sales to the telecommunications market. Engineering revenue for the three months ended January 31, 2001 was \$6,852,000 as compared to \$5,323,000 for the same period last year, an increase of 29%. The increase was primarily due to customer funded projects for developing imaging products and Media Gateway systems. Other revenue represents revenue from the Hotel operation.

Product cost of sales was 65% of product revenue for the third quarter of fiscal 2001, versus 62% for the third quarter of the prior year. The increase in product cost was primarily due to higher manufacturing costs and changes in product mix. Engineering cost of sales was 78% of engineering revenue for the third quarter of fiscal 2001 as compared to 82% for the same period last year. Other cost of sales represents operating costs associated with the Hotel operation.

## Table of Contents

Research and product development expenses for the third quarter of fiscal 2001 were \$10,569,000, as compared to \$8,382,000, for the same period last year. The increase of \$2,187,000 was due to continuing research and development activities across all of the Company product lines. Research and product development expenses were 12% of total revenue for the third quarter of fiscal 2001 and 11% for fiscal 2000.

Selling and marketing expenses for the third quarter of fiscal 2001 were \$8,612,000, or 10% of total revenue, as compared to \$6,728,000 or 9% of total revenue, for the same period last year. The increase of \$1,884,000 was due to higher personnel-related costs of approximately \$799,000 to support Camtronics expanding its direct selling operations. The remaining increase of \$1,085,000 was primarily due to selling and marketing to support the Company's revenue growth.

General and administrative expenses for the third quarter of fiscal 2001 were \$7,909,000, as compared to \$6,396,000, for the same period last year, or 9% of total revenue in both periods. The increase of \$1,513,000 was primarily due to higher personnel and other related costs to support the Company's growth.

Computer Software costs of \$726,000 and \$953,000 were capitalized in the third quarter of fiscal 2001 and 2000, respectively. Amortization of capitalized software amounted to \$293,000 and \$423,000 in the third quarter of fiscal 2001 and 2000, respectively, and is included in research and product development expenses.

Interest income, net of interest expense, for the third quarter of fiscal 2001 was \$1,314,000, as compared with \$1,404,000 for the same period last year. Interest income, net represents primarily interest earned on marketable securities.

During the third quarter of fiscal 2001, the Company recorded a gain of \$1,331,000 related to equity in unconsolidated affiliates. This gain consists primarily of \$525,000 from the Company's share of profit in a joint venture, a gain of \$15,000 reflecting the Company's share of profits in SAHCO, and a gain of \$810,000 resulting from the sale of a 5.4% equity interest in SAHCO to a group of investors. During the three months ended April 30, 2000, the Company recorded a loss of \$137,000 related to equity in its unconsolidated affiliates. The Company recorded a loss in a joint venture of \$485,000 related to research and development costs for the design and manufacture of medical equipment. This loss was partially offset by a gain of \$450,000 reflecting the Company's investment share of profit in SAHCO.

Other expenses of \$94,000 for the third quarter ended April 30, 2001 are mainly related to a writedown of approximately \$155,000 reflecting the difference between the Company's investment cost and the current market value of the restricted securities the Company received during fiscal 2000 as a final distribution of shares in a publicly traded company made by a limited partnership in which the Company had invested.

The effective tax rate for the third quarter of fiscal 2001 and 2000 was 27% and 31%, respectively. The decrease was due to an increase in the utilization of a federal research and development credits.

Net income for the third quarter ended April 30, 2001 was \$4,269,000 or \$.33 per diluted share as compared with \$4,997,000 or \$.39 per share for the same period last year. The decrease of \$728,000 in net income over the prior year was primarily attributable to a reduction in revenue and gross margin due to the downturn in demand for Industrial Technology and Signal Processing Products, which are sold primarily to the semiconductor and telecommunications industries, increased operating expenses, the writedown of the investment in restricted securities received from a limited partnership, partially offset by the Company's share of profit in SAHCO.



## **Table of Contents**

### **Financial Condition**

Cash generated by operations in the first nine months of fiscal 2001 was \$7,381,000 compared to \$974,000 used in operations during the same period of the prior year. This increase was primarily the result of improved operating income and increased income from equity investments. Operating cash flow generated by the Company along with maturities of marketable securities of \$10,320,000 was used to invest in property, plant and equipment of \$11,940,000, pay dividends of \$2,714,000, and fund other investing and financing activities.

The Company's balance sheet reflects a current ratio of 6.1 to 1 at April 30, 2001 compared to 6.0 to 1 at July 31, 2000. Liquidity is sustained principally through funds provided from operations, with short-term time deposits and marketable securities available to provide additional sources of cash. The Company places its cash investments in high credit quality financial instruments and, by policy, limits the amount of credit exposure to any one financial institution. The Company's debt to equity ratio was 0.21 to 1 at April 30, 2001 and 0.20 to 1 at July 31, 2000. Management does not anticipate any difficulties in financing operations at anticipated levels.

The carrying amounts reflected in the consolidated balance sheets of cash and cash equivalents, trade receivables, and trade payables approximate fair value at April 30, 2001 due to the short maturities of these instruments.

The Company maintains a bond investment portfolio of various issuers, types, and maturities. The Company's cash and investments include cash equivalents, which the Company considers to be investments purchased with original maturities of three months or less. Investments having original maturities in excess of three months are stated at amortized cost, which approximates fair value, and are classified as available for sale. A rise in interest rates could have an adverse impact on the fair value of the Company's investment portfolio. The Company does not currently hedge these interest rate exposures.

Accounts and notes receivable increased \$5,335,000 during the nine months ended April 30, 2001, primarily due to revenue increase. The days sales outstanding (DSO) increased from 61 to 62 days during this period.

Inventory increased \$10,426,000 during the nine months ended April 30, 2001 primarily due to increased raw materials. During this period the Company made the decision to procure adequate supplies of key components to ensure that it could meet customer requirements and support the Company's revenue growth.

The Company's Danish subsidiary B-K Medical A/S announced in May 2001 the construction of a new 135,000 square foot facility in Herlev, north of Copenhagen, for the manufacture of specialized diagnostic ultrasound equipment at an estimated cost of \$15.5 million. The new facility, due for completion in April 2002, will host manufacturing, R&D, service, marketing, sales and administrative functions.

During October 2000, Analogic Scientific, Inc. (ASI), a joint venture corporation located in The People's Republic of China, entered into separate agreements with four investors which resulted in these investors buying an 10.8% equity interest in ASI from its existing investors. This transaction had the approval of the Company and the other shareholder who prior to this transaction each had a 50% equity ownership interest in ASI. As a result, the Company's ownership in ASI was reduced by 5.4% to 44.6%. On January 18, 2001, the company name was changed from Analogic Scientific, Inc. to Shenzhen Anke High-Tech Co., Ltd (SAHCO).

## Edgar Filing: ANALOGIC CORP - Form 10-Q/A

The Company accounts for this investment under the equity method of accounting whereby the Company adjusts its investment balance to recognize its share of SAHCO's earnings or losses, changes in SAHCO's capital investment and dividends received.

SAHCO has historically provided the Company with current quarterly information regarding its financial results. To ensure that the Company has adequate time to review and adjust the financial information provided by SAHCO to conform it to U.S. Generally Accepted Accounting Principles (GAAP), the Company changed, effective with the quarter ended October 31, 2000 its method of recording SAHCO's financial results and will use the previous quarters financial information of SAHCO to adjust its investment account in the current quarter, thereby resulting in a consistently applied quarterly delay in recording its equity-based accounting.

## **Table of Contents**

During fiscal 2001 the Company became aware of certain differences between local statutory accounting practices used by SAHCO and GAAP primarily with respect to the valuation of accounts receivable and inventory and revenue recognition. During the quarter ended January 31, 2001, the Company evaluated the potential differences in accounting basis and concluded that adjustments were necessary for prior periods resulting in a reduction in the Company's investment in SAHCO of \$2,375,000 at July 31, 2000 (or \$1,808,000 net of tax effect) which reduced the carrying value of the Company's investment at July 31, 2000 from \$6,125,000 to \$3,750,000.

As a result of the sale of a 5.4% equity interest in SAHCO the Company recognized a gain of \$810,000 in the quarter ended April 30, 2001. In addition the Company recognized in the quarter ended April 30, 2001 its share of SAHCO's quarterly profit of \$15,000. The carrying value of the Company's investment in SAHCO at April 30, 2001 was \$3,225,000.

Other assets increased \$458,000 for the nine months ending April 30, 2001. The increase was primarily due to goodwill of \$473,000, net of amortization, resulting from Camtronics' acquisition of certain assets and property rights related to a third party proprietary product which will be sold by Camtronics.

## **Forward Looking Statements**

This Amendment No. 1 to Quarterly Report on Form 10-Q/A contains statements which, to the extent that they are not recitation of historical facts, constitute forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that all forward-looking statements, including statements about product development, market and industry trends, strategic initiatives, regulatory approvals, sales, profits, expenses, price trends, research and development expenses and trends, and capital expenditures involve risk and uncertainties, and actual events and results may differ significantly from those indicated in any forward-looking statements as a result of a number of important factors, including those discussed below and elsewhere herein.



Table of Contents**RISK FACTORS**

**YOU SHOULD CAREFULLY CONSIDER THE RISKS DESCRIBED BELOW BEFORE MAKING AN INVESTMENT DECISION. ADDITIONAL RISKS NOT PRESENTLY KNOWN TO US OR THAT WE CURRENTLY DEEM IMMATERIAL MAY ALSO IMPAIR OUR BUSINESS. ANY OF THESE RISKS COULD HAVE A MATERIAL AND NEGATIVE EFFECT ON OUR BUSINESS, FINANCIAL CONDITION OR RESULTS OF OPERATIONS.**

**Because a significant portion of our revenue currently comes from a small number of customers, any decrease in revenue from these customers could harm our operating results.**

We depend on a small number of customers for a large portion of our business, and changes in our customers' orders may have a significant impact on our operating results. If a major customer significantly reduces the amount of business it does with us, there would be an adverse impact on our operating results. The following table sets forth the percentages of our total net sales for our three largest customers in any of the last three fiscal years and the percentage of our total net sales to our ten largest customers in those years:

	Year ended July 31,		
	2000	1999	1998
Philips	16%	18%	16%
General Electric	10%	8%	8%
Toshiba	9%	9%	
Imation			7%
Ten largest customers as a group	60%	60%	56%

Although we are seeking to broaden our customer base, we will continue to depend on sales to a relatively small number of major customers. Because it often takes significant time to replace lost business, it is likely that our operating results would be adversely affected if one or more of our major customers were to cancel, delay or reduce significant orders in the future. Our customer agreements typically permit the customer to discontinue future purchases after timely notice.

In addition, we generate significant accounts receivable in connection with the products we sell and the services we provide to our major customers. Although our major customers are large corporations, if one or more of our customers were to become insolvent or otherwise be unable to pay for our services, our operating results and financial condition could be adversely affected.

**Competition from existing or new companies in the medical instrumentation technology industry could cause us to experience downward pressure on prices, fewer customer orders, reduced margins, the inability to take advantage of new business opportunities and the loss of market share.**

We operate in a highly competitive industry. We are subject to competition based upon product design, performance, pricing, quality and service and we believe our innovative engineering and product reliability have been important factors in our growth. While we try to maintain

## Edgar Filing: ANALOGIC CORP - Form 10-Q/A

competitive pricing on those products which are directly comparable to products manufactured by others, in many instances our products will conform to more exacting specifications and carry a higher price than analogous products manufactured by others.

Our competitors include divisions of some larger, more diversified organizations as well as several specialized companies. Some of them have greater resources and larger staffs than we have.

## **Table of Contents**

Many of our OEM customers and potential OEM customers have the capacity to design and manufacture the products we manufacture for themselves. We face competition from research and product development groups and the manufacturing operations of our current and potential customers, who continually evaluate the benefits of internal research and product development and manufacturing versus outsourcing.

**We depend on our suppliers, some of which are the sole source for our components, and our production would be substantially curtailed if these suppliers are not able to meet our demands and alternative sources are not available.**

We order raw materials and components to complete our customers' orders, and some of these raw materials and components are ordered from sole-source suppliers. Although we work with our customers and suppliers to minimize the impact of shortages in raw materials and components, we sometimes experience short-term adverse effects due to price fluctuations and delayed shipments. In the past, there have been industry-wide shortages of electronics components. If a significant shortage of raw materials or components were to occur, we may have to delay shipments or pay premium pricing, which would adversely affect our operating results. In some cases, supply shortages of particular components will substantially curtail production of products using these components. We are not always able to pass on price increases to our customers. Accordingly, some raw material and component price increases could adversely affect our operating results. We also depend on a small number of suppliers, some of whom are affiliated with customers or competitors and others of whom may be small, poorly financed companies, for many of the other raw materials and components that we use in our business. If we are unable to continue to purchase these raw materials and components from our suppliers, our operating results would be adversely affected. Because many of our costs are fixed, our margins depend on our volume of output at our facilities and a reduction in volume will adversely affect our margins.

**If we are left with excess inventory, our operating results will be adversely affected.**

Because of long-lead times and specialized product designs, we typically purchase components and manufacture products for customer orders or in anticipation of customer orders based on customer forecasts. For a variety of reasons, such as decreased end-user demand for the products we are manufacturing, our customers may not purchase all of the products we have manufactured or for which we have purchased components. In either event, we would attempt to recoup our materials and manufacturing costs by means such as returning components to our vendors, disposing of excess inventory through other channels or requiring our OEM customers to purchase or otherwise compensate us for such excess inventory. Some of our significant customer agreements do not give us the ability to require our OEM customers to do this. To the extent we are unsuccessful in recouping our material and manufacturing costs, not only would our net sales be adversely affected, but also our operating results would be disproportionately adversely affected. Moreover, carrying excess inventory would reduce the working capital we have available to continue to operate and grow our business.

**Uncertainties and adverse trends affecting our industry or any of our major customers may adversely affect our operating results.**

Our business depends primarily on a specific segment of the electronics industry, medical instrumentation technology products, which is subject to rapid technological change and pricing and margin pressure. This industry has historically been cyclical and subject to significant downturns characterized by diminished product demand, rapid declines in average selling prices and production over-capacity. In addition, changes in government policy relating to reimbursement for the purchase and use of medical capital equipment could also affect our sales. Our customers markets are also subject to economic cycles and are likely to experience recessionary periods in the future. The economic conditions affecting our industry, in general, or any of our major customers, in particular, may adversely affect our operating results. Our businesses outside the medical instrumentation technology product sector are subject to the same or greater technological and cyclical pressures.

## **Table of Contents**

**Our customers' delay or inability to obtain any necessary United States or foreign regulatory clearances or approvals for their products could have a material adverse effect on our business.**

Our products are used by a number of our customers in the production of medical devices that are the subject of a high level of regulatory oversight. A delay or inability to obtain any necessary United States or foreign regulatory clearances or approvals for products could have a material adverse effect on our business. The process of obtaining clearances and approvals can be costly and time-consuming. There is a further risk that any approvals or clearances, once obtained, may be withdrawn or modified. Medical devices cannot be marketed in the United States without clearance or approval by the FDA. Medical devices sold in the United States must also be manufactured in compliance with FDA Good Manufacturing Practices, which regulate the design, manufacture, packing, storage and installation of medical devices. Moreover, medical devices are required to comply with FDA regulations relating to investigational research and labeling. States may also regulate the manufacture, sale and use of medical devices. Medical device products are also subject to approval and regulation by foreign regulatory and safety agencies.

**Our quarterly operating results are subject to fluctuations, which could affect the market price of our common stock.**

Our annual and quarterly results may vary significantly depending on various factors, many of which are beyond our control, and may not meet the expectations of securities analysts or investors. If this occurs, the price of our common stock would likely decline.

These factors include:

variations in the timing and volume of customer orders relative to our manufacturing capacity;

introduction and market acceptance of our customers' new products;

changes in demand for our customers' existing products;

the timing of our expenditures in anticipation of future orders;

effectiveness in managing our manufacturing processes;

changes in competitive and economic conditions generally or in our customers' markets;

changes in the cost or availability of components or skilled labor; and

foreign currency exposure.

As is the case with many technology companies, we typically ship a significant portion of our products in the last month of a quarter. As a result, any delay in anticipated sales is likely to result in the deferral of the associated revenue beyond the end of a particular quarter, which would have a significant effect on our operating results for that quarter. In addition, most of our operating expenses do not vary directly with net sales and

## Edgar Filing: ANALOGIC CORP - Form 10-Q/A

are difficult to adjust in the short term. As a result, if net sales for a particular quarter were below our expectations, we could not proportionately reduce operating expenses for that quarter, and, therefore, that revenue shortfall would have a disproportionate adverse effect on our operating results for that quarter.

**Table of Contents**

**Loss of any of our key personnel could hurt our business because of their industry experience and their technological expertise.**

We operate in a highly competitive industry and depend on the services of our key senior executives and our technological experts. The loss of the services of one or several of our key employees or an inability to attract, train and retain qualified and skilled employees, specifically engineering and operations personnel, could result in the loss of customers or otherwise inhibit our ability to operate and grow our business successfully.

**If we are unable to maintain our technological expertise in research and product development and manufacturing processes we will not be able to successfully compete.**

We believe that our future success will depend upon our ability to provide research and product development and manufacturing services that meet the changing needs of our customers. This requires that we successfully anticipate and respond to technological changes in design and manufacturing processes in a cost-effective and timely manner. As a result, we continually evaluate the advantages and feasibility of new product design and manufacturing processes. We cannot, however, provide assurance that our development efforts will be successful.

**Table of Contents**

**PART II OTHER INFORMATION**

**Item 6. Exhibits and Reports on Form 8-K**

(a) Exhibits

<u>Exhibit</u>	<u>Description</u>
31.1	Certification of Chief Executive Officer Pursuant to Rule 13a-14(a)/Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended
31.2	Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended
32.1	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350
32.2	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350

(b) During the quarter ended April 30, 2001, the Company did not file any reports on Form 8-K.

Table of Contents

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Amendment to be signed on its behalf by the undersigned thereunto duly authorized.

ANALOGIC CORPORATION  
Registrant

/s/JOHN W. WOOD JR.

---

John W. Wood Jr.  
*President and Chief Executive Officer*  
*(Principal Executive Officer)*

Date: October 27, 2003

/s/JOHN J. MILLERICK

---

John J. Millerick  
*Senior Vice President,*  
*Chief Financial Officer and Treasurer*  
*(Principal Financial and Accounting Officer)*

Date: October 27, 2003



**Table of Contents**

EXHIBIT INDEX

<b><u>Exhibit</u></b>	<b><u>Description</u></b>
31.1	Certification of Chief Executive Officer Pursuant to Rule 13a-14(a)/Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended
31.2	Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended
32.1	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350
32.2	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350